We help healthcare companies, Entrepreneurs.

Currently MEDAS actively offers consultancy services in advanced diagnostics such as molecular pathology and genomics.

We tailor MEDAS’s capability offerings to the needs of each client to help them solve problems or pursue opportunities by business need:

1. Expert Advice to Investors: For Mergers & Acquisitions (M&A Strategy)

2. Expert Advice for Startups: Technology Evaluation & liaison for go to market strategy

3. Technical Advise in Capability Evaluation: Molecular Diagnostics & Clinical Genomics

4. Strategic Directives in the area of Diagnostics: Infectious Diseases, Oncology and Genetic Disorders

5. Translational Focus: For Bio-tech Companies – Technical assessment, Quality evaluation and Readiness of the Product for implementation in the market.

The question isn’t whether to do deals but how to do them so that they create sustainable value. Our answer: Use M&A as an integral part of your global growth strategy, plan for opportunities long before they arise, and build a repeatable acquisition model honed through frequent, continuous deal making. We’ll work with you to:

Advise on strategy and screening, due diligence, integration, divestitures and separations, joint ventures/alliances, corporate finance, and much more.

Apply a comprehensive set of best-in-class diagnostics, frameworks, proprietary benchmarks and other analytics tools and capabilities to guide target prioritization and screening, integration workflows and other essential elements of successful M&A.

Our M&A advisory expert can help you every step of the way to:

Improve your odds of success by honing your M&A strategy and objectives, developing your M&A team and capabilities, and building a repeatable process.

Take capability evaluation to the next level with a fact-based, rigorously quantified assessment that helps you to prepare for integration long before the deal is inked.

Capture maximum value from corporate acquisitions with a battle-tested approach to integration that mitigates the many risks that can undercut a deal’s anticipated synergies. Companies that turn to MEDAS for Evaluation of the healthcare model and technology evaluation can achieve exactly that.

Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value. Despite its policy goals, HTA must always be firmly rooted in research and the scientific methods”. HTA tries to support policy makers in making good decisions by providing them with objective, transparent, and scientifically based information in order to encourage the use of safe, better and acceptable interventions.

 The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow etc., the economic value needs to be demonstrated to healthcare payers.

MEDAS offers tailor-made Health Technology Assessment expertise through:

• Development-focused health technology assessment: even in the early stages of development when complete clinical data is not (yet) available, an estimation of expected value can be made using experts-inputs and small scale studies.

• Extensive literature review of the relevant standard of care pathway and associated costs, establishing the baseline to which your innovation will be compared by payers.

• Developing, analyzing and validating health economic models, including translating and updating existing models with new (country-specific) data.

• Development of value dossiers for all relevant stakeholders. (In cooperation)

The triad of quality, innovation and economic restraint is as important in health care as it is in the business world. We therefore propose a strategy and new structures to standardize the description of health care innovations and to quantify them.

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry. If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from MEDAS’s Health Innovation Assessment solution.

By making use of robust methods to collect and analyze data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making. Where Medical Technology Assessment (MTA) or Health Technology Assessment (HTA) address value assessment of innovations for primarily scientific interest, HIA supports innovators and their stakeholders to make better-informed decisions about the value of innovations. HIA makes use of health economics, health services and policy research, market access analysis, and implementation science.

The core objective of the go-to-market strategy is the creation and expansion of competitive advantages in the development of a market. The focus on promising market and customer segments and the optimal positioning of the product range vis-à-vis the competition form the foundation for sustainable growth.

This growth strategy is of essential importance. It defines future fields of activity and determines success in a changing market environment. We help you to find the right balance in the portfolio of market segments in terms of growth potential, economic stability, competitive intensity, etc. on the basis of market, trend and attractiveness analyses. We align the strategy and product placement in cohesion with technology assessment  of your product with the market requirements and consider all market-related functions and success factors for scaling.

The competitive strategy can focus on individual products, the entire company or a portfolio of companies or investments. Customer requirements along the journey play a key role in this. Only those who know the requirements and effects on the customer’s success and are able to assess their own performance against the competition will prevail in the long term. This strategy demands experiences, cleverness and creativity. Does our product and service portfolio fit the requirements of our customers? Which strategies do we pursue to optimize the customer or product lifetime value and how do these affect new business and after-sales? How can we generate and market additional customer value with our data history and application knowledge?

At MEDAS we work in putting together an agile GTM strategy that bundles central thrusts and provides custom approaches for your product and portfolio.